Subgroup | N | SEN (95% CI) | SPE (95% CI) | PLR (95% CI) | NLR (95% CI) | DS (95% CI) | DOR (95% CI) | AUC (95% CI) | P a |
---|---|---|---|---|---|---|---|---|---|
Overall | 13 | 0.79 (0.71–0.85) | 0.87 (0.74–0.94) | 6.08 (2.77–13.36) | 0.24 (0.17–0.35) | 3.22 (2.19–4.24) | 24.91 (8.91–69.66) | 0.84 (0.81–0.87) |  |
Geographic area | |||||||||
 Europe | 5 | 0.80 (0.66–0.89) | 0.86 (0.56–0.97) | 5.80 (1.46–23.10) | 0.23 (0.13–0.43) | 3.21 (1.51–4.91) | 24.81 (4.53–135.75) | 0.86 (0.83–0.89) | NC |
 Oceania | 4b | 0.75 (0.59–0.86) | 0.77 (0.61–0.87) | 3.22 (1.70–6.08) | 0.33 (0.18–0.61) | 2.28 (1.11–3.45) | 9.78 (3.04–31.47) | 0.80 (0.77–0.84) |  |
 South America | 1 | 0.78 | 0.91 | 8.56 | 0.24 | −c | 35.00 | – |  |
 Africa | 4b | 0.94 (0.44–1.00) | 0.98 (0.85–1.00) | 52.54 (5.96–462.88) | 0.06 (0.00–1.00) | 6.76 (3.74–9.77) | 861.19 (42.25–17,552.00) | 0.99 (0.98–1.00) |  |
 North America | 4b | 0.77 (0.69–0.84) | 0.87 (0.64–0.96) | 6.11 (1.79–20.94) | 0.26 (0.16–0.41) | 3.17 (1.54–4.79) | 23.70 (4.68–120.00) | 0.83 (0.79–0.86) |  |
 Asia | 1 | 0.82 | 0.70 | 2.77 | 0.26 | – | 10.75 | – |  |
Preparation method | |||||||||
 No preparation | 1 | 0.71 | 0.55 | 1.58 | 0.53 | – | 3.00 | – | NC |
 One preparation | 11 | 0.82 (0.73–0.88) | 0.87 (0.73–0.94) | 6.10 (2.84–13.09) | 0.21 (0.14–0.33) | 3.36 (2.32–4.39) | 28.70 (10.21–80.65) | 0.88 (0.85–0.91) |  |
 Double preparation | 1 | 0.63 | 1.00 | – | 0.40 | – | – | – |  |
AR trigger | |||||||||
 Physiological trigger | 10b | 0.82 (0.73–0.88) | 0.88 (0.76–0.94) | 6.78 (3.10–14.83) | 0.20 (0.13–0.33) | 3.50 (2.35–4.65) | 32.26 (10.53–105.06) | 0.89 (0.86–0.91) | NC |
 Nonphysiological trigger | 8 | 0.79 (0.70–0.85) | 0.86 (0.65–0.95) | 5.70 (1.98–16.39) | 0.25 (0.16–0.37) | 3.14 (1.82–4.46) | 23.10 (6.16–81.56) | 0.82 (0.78–0.85) |  |
AR assay method | |||||||||
 Fluorescent labels | 11 | 0.78 (0.71–0.84) | 0.90 (0.78–0.96) | 8.01 (3.24–19.82) | 0.24 (0.18–0.34) | 3.49 (2.35–4.64) | 32.83 (10.44–103.21) | 0.83 (0.80–0.86) |  |
  Direct immunofluorescence | 10 | 0.78 (0.70–0.85) | 0.86 (0.74–0.93) | 5.72 (2.81–11.63) | 0.25 (0.17–0.37) | 3.12 (2.11–4.14) | 22.76 (8.23–62.95) | 0.84 (0.81–0.87) |  |
   FITC−PSA | 7 | 0.81 (0.69–0.88) | 0.83 (0.66–0.93) | 4.80 (2.09–11.01) | 0.23 (0.13–0.41) | 3.02 (1.72–4.32) | 20.51 (5.60–75.15) | 0.87 (0.83–0.89) |  |
   FITC−PNA | 4b | 0.68 (0.58–0.76) | 0.85 (0.81–0.88) | 4.55 (3.42–6.05) | 0.38 (0.28–0.50) | 2.49 (1.98–3.01) | 12.10 (7.24–20.21) | 0.85 (0.81–0.87) |  |
   RITC−PSA | 1 | 0.83 | 0.98 | 38.33 | 0.17 | – | 225.00 | – |  |
  Indirect immunofluorescence | |||||||||
   Anti−CD46 antibody | 1 | 0.83 | 1.00 | – | 0.18 | – | – | – |  |
 Triple stain | 4b | 0.93 (0.76–0.98) | 0.58 (0.52–0.64) | 2.23 (1.96–2.54) | 0.12 (0.03–0.43) | 2.92 (1.59–4.25) | 18.56 (4.91–70.16) | 0.68 (0.64–0.72) |  |